Zacks Research Issues Pessimistic Forecast for TEVA Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) – Stock analysts at Zacks Research decreased their Q3 2025 EPS estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Thursday, September 4th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.66 for the quarter, down from their previous forecast of $0.69. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q1 2026 earnings at $0.51 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.75 EPS and Q4 2026 earnings at $0.71 EPS.

Several other research firms have also recently weighed in on TEVA. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a “buy” rating and a $25.00 price objective for the company. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a “buy” rating and a $24.00 target price on the stock. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Buy” and a consensus price target of $24.71.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $18.94 on Monday. The stock has a market cap of $21.72 billion, a P/E ratio of -118.35, a PEG ratio of 1.12 and a beta of 0.72. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The business’s 50-day moving average price is $17.04 and its two-hundred day moving average price is $16.39. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter last year, the business posted $0.61 earnings per share. The firm’s revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Ion Asset Management Ltd. lifted its position in Teva Pharmaceutical Industries by 6.5% in the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock valued at $599,945,000 after purchasing an additional 2,383,500 shares during the last quarter. Menora Mivtachim Holdings LTD. increased its stake in shares of Teva Pharmaceutical Industries by 31.9% in the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after buying an additional 9,303,978 shares during the period. Phoenix Financial Ltd. raised its holdings in Teva Pharmaceutical Industries by 31.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock valued at $632,882,000 after buying an additional 9,094,372 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Teva Pharmaceutical Industries by 51.4% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock valued at $559,622,000 after buying an additional 11,334,780 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in Teva Pharmaceutical Industries by 8.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company’s stock valued at $480,768,000 after buying an additional 2,350,000 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Placid Jover sold 6,053 shares of the firm’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.